Omalizumab

Children and adolescents with allergic asthma and serum IgE levels that exceed approved dosing ranges still benefitted from omalizumab, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Patients with asthma treated with biologics did not have higher rates of SARS-CoV-2 infection than the general population, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Patients who began taking or who switched biologics for severe asthma consistently experienced meaningfully reduced exacerbations, according to a real-world analysis published in Annals of Allergy, Asthma & Immunology.

Patients with chronic rhinosinusitis with nasal polyps tolerated treatment with biologics with decreased risks for asthma exacerbation and worsening nasal polyps, according to a study published in Clinical and Translational Allergy.

Patients with chronic spontaneous urticaria demonstrated improved outcomes related to idiopathic angioedema after taking omalizumab, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

A dose of omalizumab administered before pollen season improved symptom control and quality of life compared with standard medication among patients with seasonal allergic rhinitis, according to a study in Clinical and Translational Allergy.

Omalizumab benefited patients with moderate to severe allergic asthma regardless of their BMI, according to a study published in Annals of Allergy, Asthma & Immunology.

Ligelizumab and omalizumab were found to be the most effective treatments for adolescent and adult patients with chronic spontaneous urticaria who had failed to respond to H1 antihistamines, according to a study.

Omalizumab effectively treated chronic cold urticaria and prevented further episodes of anaphylaxis, according to a single-center study published in The Journal of Allergy and Clinical Immunology: In Practice.

Omalizumab may effectively treat idiopathic anaphylaxis in patients without indication of mast cell clonality and who have failed on prior treatments, according to study results published in Annals of Allergy, Asthma & Immunology.